Wenqing He

Wenqing He

Auto-generated profile, based on publicly available information

Wenqing He

Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
WHWenqing He
Wenqing He
JWJiajia Wang
Jiajia Wang
ZFZhenzhen Feng
Zhenzhen Feng
JLJiansheng Li
Jiansheng Li
YXYang Xie
Yang Xie
Objective: Pulmonary rehabilitation (PR) has been considered to be an effective treatment method for various respiratory diseases. However, the effects of exercise-based PR on patients with severe/very severe chronic obstructive pulmonary disease (COPD) are unclear. This review aimed to investigate the effects of exercise-based PR on patients with severe/very severe COPD. Methods: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases were searched from inception to December 23, 2022, without language restrictions. Randomized controlled trials (RCTs) investigating the effects of exercise-based PR on patients with severe/very severe COPD were included. Study selection, data extraction, and risk of bias assessment were conducted independently. RevMan software (version 5.3) was used for meta-analysis. The quality of evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation system. Results: Six studies (263 patients) were identified. Compared with the control group, the 6-min walking distance [MD = 52.91, 95% CI (3.80, 102.03)], the St. George’s Respiratory Questionnaire total scores [MD = −7.70, 95% CI (−14.32, −1.08)] and the Borg scale scores [MD = −0.68, 95% CI (−1.28, −0.08)] in the experimental group improved, respectively. The St. George’s Respiratory Questionnaire and Borg scale scores were rated as ‘moderate quality’ and ‘low quality’, respectively, and the 6-min walking distance was rated as ‘very low quality’. Conclusions: Exercise-based PR may improve the exercise capacity, quality of life and dyspnea of patients with severe/very severe COPD, which can be regarded as an adjuvant treatment. High quality and large sample RCTs are needed. Registration: This systematic review and meta-analysis protocol was prospectively registered with PROSPERO (No. CRD42022294085).

10 August 2026 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
YXYang Xie
Yang Xie
WHWenqing He
Wenqing He
Hejia WanHejia Wan
Hejia Wan
RZRuifang Zhou
Ruifang Zhou
JWJiaJia Wang
JiaJia Wang
JLJiansheng Li
Jiansheng Li
Objectives: To evaluate, from a Chinese healthcare system perspective, the cost-utility of three treatment strategies (Western medicine, Traditional Chinese Medicine [TCM], and combined therapy) for stable chronic obstructive pulmonary disease (COPD) using a discrete event simulation (DES) model parameterized with clinical trial data. Methods: A DES model was developed for stable COPD patients (aged 18–80 years) from a Chinese healthcare system perspective. The model incorporated 24 baseline variables, six intermediate outcomes (FEV1, 6MWD, dyspnea, cough, sputum, COPD-PRO), and acute exacerbation as the final outcome. Multilevel mixed-effects models and Weibull regression updated these longitudinal outcomes every three months over a 2-year time horizon. Health outcomes were measured as quality-adjusted life years (QALYs), the primary outcome of the economic evaluation. Costs were estimated in 2013 RMB and adjusted to 2022 values using the China Consumer Price Index (CPI). Results: In the three-month base-case analysis, patients with COPD showed a mean 6.8 m increase in six-minute walk distance (6MWD), 0.25 fewer acute exacerbations, and improved symptom scores. The mean two-year total cost was 12,726.18 RMB. Cost-utility ratios (CURs) were 5,066.79, 4,477.09, and 4,540.93 RMB/QALY for the Western medicine, TCM, and combined therapy groups, respectively. Compared with the TCM group, the combined therapy group incurred an additional 448 RMB and gained 0.060 additional QALYs, yielding an incremental cost-utility ratio (ICUR) of 7,467 RMB/QALY; Western medicine alone was dominated. At a willingness-to-pay (WTP) threshold of 85,698 RMB/QALY (1x China’s per-capita GDP), the probability that combined therapy was cost-effective was 98.5% in probabilistic sensitivity analysis (400 iterations). Conclusions: The DES model was useful for the health-economic evaluation of TCM in COPD. The 0.060 QALY gain associated with combined therapy corresponds to approximately 22 days in full health and falls within the reported minimum clinically important difference (MCID) range for COPD (0.03–0.07 QALY), suggesting that the benefit may be clinically perceptible at the group level; individual-level variation nonetheless warrants caution. These exploratory findings, which carry potential overfitting risk given the single-trial design, require validation in larger, geographically diverse multi-center studies.
1